Earnings call
Sun Pharmaceutical Industries Q1 FY27 earnings call: Sun Pharmaceutical Industries Limited's sales in Q1 FY27 were INR1,51,836 million, up 10.1% versus Q1 financial year FY26
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
Sales in Q1 FY27 were INR1,51,836 million, up 10.1% versus Q1 financial year FY26. The company became the number 2 generic semaglutide injectable player during Q1 FY27. The company launched 2 generic products in the U.S. in Q2. The company had net cash of $3.4 billion at the consolidated level.
The numbers management gave
Results
- Sales in Q1 FY27 were INR1,51,836 million, up 10.1% versus Q1 financial year FY26.
Show source
During the first quarter of FY27, sales were at INR1,51,836 million, registering a growth of 10.1% versus Q1 financial year FY26.
- Gross margin in Q1 FY27 was 80.5%, higher than the same period last year, mainly on account of better product mix.
Show source
Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY27 Earnings Call Transcript 06:30 pm July 31, 2026 Gross margin was at 80.5% for the quarter, higher than the same period last year, mainly on account of better product mix.
- EBITDA in Q1 FY27 was INR 44,177 million, an increase of 2.7% over Q1 last year.
Show source
EBITDA for the quarter was INR 44,177 million, an increase of 2.7% over Q1 last year.
- EBITDA margin in Q1 FY27 was 28.9%; the margin was slightly lower, as Q1 FY26 had some benefit from Lenalidomide sales.
Show source
EBITDA margins came in at 28.9% while EBITDA margins were slightly lower, please note that Q1 FY26 had some benefit from Lenalidomide sales.
- Effective tax rate in Q1 FY27 was 27.8%, versus 24.3% in Q1 FY26, as Sun had a significantly lower tax rate in India that is now getting exhausted and varying tax rates across jurisdictions moved the effective tax rate up.
Show source
Effective tax rate for the quarter was at 27.8% versus 24.3% in Q1 FY26.
- Innovative medicine sales in Q1 FY27 were USD351 million, up 12.8%, and accounted for 21.9% of Sun sales for the quarter.
Show source
In Q1 FY27, our innovative medicine sales were up 12.8% to reach USD351 million.
Show 8 more statements
Results
- India formulations sales in Q1 FY27 were INR54,749 million, recording growth of 16% and accounting for 36.1% of its total consolidated sales for the quarter.
Show source
Sales of India formulations were INR54,749 million for the quarter, recording a growth of 16%.
- Leqselvi surpassed 1,000 prescribers in June and delivered its strongest month since launch, demonstrating increased adoption and growing confidence in the brand.
Show source
In the month of June, we surpassed 1,000 prescribers, and we also delivered our strongest month since launch, demonstrating increased adoption and growing confidence in the brand.
- Consolidated R&D investments in Q1 FY27 were INR8,264 million, or 5.4% of sales, and innovative R&D accounted for 30% of its total R&D spend.
Show source
Consolidated investments towards R&D for Q1 FY27 stands at INR8,264 million or 5.4% of sales.
- Volume and new product growth accounted for 50% of its growth in Q1 FY27.
Show source
So 50% of our growth is comin g from volume and new products.
- Volume growth accounted for 40% and new products accounted for 20% of Sun Pharmaceutical Industries Limited's total growth in Q1 FY27.
Show source
So 40% from volume, 20% from new products.
- Global Innovative Medicines business growth in Q1 FY27 was driven across U.S. and ex-U.S. markets and across products, notably ILUMYA, ODOMZO and CEQUA.
Show source
The performance in Innovative Medicine business continues to be driven by growth across U.S. and ex-U.S. markets and across products, notably ILUMYA, ODOMZO and CEQUA.
- The company saw seasonality with Levulan, its product for actinic keratosis, in the past quarter and expects similar seasonality next quarter.
Show source
We would expect to see similar next quarter.
Money and capital
- The company had net cash of $3.4 billion at the consolidated level.
Show source
Balance sheet of Sun continues to be strong with a net cash of $3.4 billion at the consolidated level.
What it expects ahead
What management expects
- Until the Organon closing, Sun Pharmaceutical Industries Limited expects its tax rate to be in a similar range as in Q1.
Show source
Going forward, and until Organon closing, we expect the tax rate to be in a similar range as in Q1.
- The company maintained high single-digit growth guidance for the full year and said exchange-related impacts would affect all line items in the P&L.
Show source
Jayashree Satagopan: Think we should stick on to the high single-digit growth for the full year.
- The company expects its effective tax rate range to continue for some time until the Organon transaction is completed.
Show source
And we expect this range to sort of continue for some time until we have the Organon transaction completed.
- The company will focus on ensuring and getting semaglutide to the market and doing the best launch possible. Replaced by a later filing.
Show source
So our focus will be in ensuring and getting the product to the market and doing the best launch possible.
What it is building and selling
Demand and pricing
- The company became the number 2 generic semaglutide injectable player during Q1 FY27.
Show source
Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY27 Earnings Call Transcript 06:30 pm July 31, 2026 During the quarter, the company became number 2 generic semaglutide injectable player.
- As per Pharmarack MAT June 2026, Sun Pharmaceutical Industries Limited was ranked number 1 and held 8.5% market share in the over INR2,527 billion Indian pharmaceutical market, compared with 8.2% market share in the previous period.
Show source
Sun Pharma is ranked number 1 and holds 8.5% market share in the over INR2,527 billion Indian pharmaceutical market as per Pharmarack MAT June 2026.
- The company is number 1 in 12 therapy areas, according to SMSRC.
Show source
That's what we said in SMSRC, we are number 1 in 12 therapy areas.
Segments
- The company launched 2 generic products in the U.S. in Q2.
Show source
Recently, we have received approvals to manufacture and market the generic version of semaglutide injection in both Brazil and South Africa for the treatment of adults with Type 2 diabetes.
- The company is the only company in India offering a semaglutide auto-injector, and health care professionals gave the device positive feedback for enabling smooth initiation and significantly reducing needle phobia.
Show source
Sun Pharma is the only company in India offering semaglutide auto-injector and the device has received a positive feedback from health care professionals for enabling smooth initiation and significantly reducing needle phobia.
Deals and partners
- Partner Philogen has resubmitted Nidlegy for marketing authorization in Europe, and updated data for the resubmission is due to be published soon in a major journal.
Show source
Recently, our partner, Philogen has resubmitted Nidlegy for marketing authorization in Europe.
Everything else said on the call
Group structure
- Organon has received shareholder approval for acquisition by Sun, and the acquisition is subject to satisfaction of remaining customary closing conditions and is on track to close by early 2027.
Show source
The acquisition is subject to the satisfaction of remaining customary closing conditions and is on track to close by early 2027.
- Organon shareholders have approved the transaction, and Sun Pharmaceutical Industries Limited expects the acquisition to be completed in Q4 of financial year '27; an integration management office has been working on day one preparedness.
Show source
We expect the acquisition to be completed in Q4 of financial year '27 and an integration management office has been working on day one preparedness.
- The process of filing for regulatory approvals for the Organon transaction in various markets has been completed, and approvals have been received in certain countries.
Show source
Coming to Organon transaction, the process of filing for regulatory approvals in various markets have been completed.
Other
- At the 2026 ASCO Annual Meeting, Sun Pharmaceutical Industries Limited shared updated results from the locally advanced cutaneous squamous cell carcinoma expansion cohort of the pivotal trial of Unloxcyt; more than one in four patients achieved complete tumor response, with durable benefit and a generally manageable safety profile.
Show source
The updated data showed a durable benefit for patients with more than one in four achieving complete tumor response and generally manageable safety profile.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
There's seems to be some deceleration of growth in this segment. Is it possible for the management to give color on reasons for slower growth in 1Q?
Answer, kirti ganorkar
Kirti Ganorkar: I think our focus is on innovative business. And here, we would like the innovative business to continue to grow at a healthy rate. So we are expecting healthy growth to continue for innovative business in U.S., driven by new launches, as you know, Unloxcyt and Ilumya is also doing well. But we don't provide any product-wise revenue and growth at this moment.
Question
Amey Chalke: Sure. But any product in this quarter, particularly where you saw some impact, which could have affected the growth this quarter?
Answer, richard ascroft
Richard Ascroft: Kirti, I can… Kirti Ganorkar: Yeah, go ahead.
Answer, richard ascroft
Richard Ascroft: Sure. Kirti, I can comment on the U.S. as I shared in my comments, we do see seasonality with Levulan, our product for actinic keratosis. So as I had shared previously, we did see that seasonality this past quarter. We would expect to see similar next quarter.
Question
Amey Chalke: Sure. That's helpful. Second question I have on semaglutide. It is quite visible that sema could become a meaningful revenue driver for us, both in India and ROW. In light of this, I just wanted to understand our preparedness of the supply chain. How much supply we have been able to secure in terms of sense for the full year of FY27?
Answer, kirti ganorkar
Kirti Ganorkar: Sure. Yes, semaglutide now we are selling in India from March '26 onwards, South Africa - - we got approval last week. And as Aalok said, we already commercialized the product. And now we are preparing for the launch in Brazil through our partners. And I'm hopeful that we will meet the market demand. So we are well prepared for this launch. We have API manufactured in-house formulation also we do in-house, and we are tied up with all the people who are supplying the components for device.
Answer, kirti ganorkar
So I think we are well prepared to commercialize this opportunity in South Africa and Brazil. And India, as I said already, we are number 2 players among the all generic players.
Question
So very strong trend, and this is despite the loss of Lenalidomide sales. So in your opening remarks, you indicated product mix is the main factor to drive gross margin. So if you can elaborate a bit like which regions or which segments are really driving the growth? And are these levels sustainable?
Answer, jayashree satagopan
Jayashree Satagopan: Okay. As I was mentioning, we have seen a growth mainly driven by product mix. We've seen good growth in our branded generics business as well as our innovative medicines business. Both of these have resulted in a healthier margin profile for the quarter.
Question
Damayanti Kerai: So on a year-on-year basis, does contribution went up from both branded generics and innovative medicine at the gross profit level?
Answer, jayashree satagopan
Jayashree Satagopan: Yes. The share of business to the overall revenues have gone up. And therefore, you would see the reflection also coming in the gross margins.
Question
Damayanti Kerai: My second question is on your R&D spend. So we understand there is variability quarter- on-quarter, but how should we look at the spend on a full year basis? And you have given the pipeline as well and indicated 30% is for innovative medicine. So where is the rest 70% spend happening? Yes, that's my second question.
Answer, dilip shanghvi
Dilip Shanghvi: No, I think it's a time gap between what you call stopping some of the trials and starting some of the new indication trials. So I think don't look at the R&D spend this quarter. We have already guided for the annual number. And I think we should be able to meet those numbers.
Question
Damayanti Kerai: Okay. And remaining 70% spend is towards?
Answer, dilip shanghvi
Dilip Shanghvi: That would be generics as well as products for India.
Question
Kunal Dhamesha: First one for Rick on Leqselvi and Unloxcyt. While it has received good response from the prescriber, how is the access aspect of these two molecules moving on? Let's say, where would you want to be versus where you are currently? And how long this journey would take from improving the formulary access? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY27 Earnings Call Transcript 06:30 pm July 31, 2026 R
Answer, richard ascroft
Great question. Maybe I'll start with Leqselvi because the access is different given the different kinds of products that we have. So from a payer access, which is what's most important for Leqselvi, we continue to grow. In fact, we added an important plan just this past quarter and improved the overall access. We do already for Leqselvi now have the majority of the covered lives available to us. Unloxcyt is a bit different because it's primarily administered in the health care setting. So there, we're very focused on formulary access at the cancer centers as well as the large integrated delivery networks within the U.S. And similarly, we have progressed quite rapidly actually in terms of getting the product added on those formularies.
Answer, richard ascroft
I think really in recognition of the differentiation that the clinicians see. It's a different mechanism of action. And so you have this durable efficacy, but what's quite interesting about Unloxcyt is you don't see the typical immune-mediated adverse events, particularly the Grade 4 and 5, which is why the product is being added to formularies.
Question
Kunal Dhamesha: And Rick, just for the understanding for Unloxcyt, who is the decision-maker, is it doctor who makes the decision? Or is it the cancer center, which will have a few PD-1 or PD-L1s on their formularies and then doctor needs to prescribe from that list? How does it work?
Answer, richard ascroft
Richard Ascroft: It's a bit of a combination. In most of the centers, there is a formulary, but that formulary is heavily influenced by the clinicians and what products they want to use on the formulary. So we're working directly with the administrators of those institutions as well as oncologists so they can ensure they have access to the product.
Question
Kunal Dhamesha: Sure. We have… Richard Ascroft: I should add, though, we also have good commercial coverage as well.
Answer, richard ascroft
So -- but yes, due to the age of the population, they tend to be Medicare beneficiaries. And because the product is infused, it is a Part B as in boy product.
Show 18 more questions
Question
Kunal Dhamesha: Sure. Second question is for ma'am on other expenses. I think we had suggested that other expenses would come down, and it has come down on a sequential basis. But from here on, how should we look Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY27 Earnings Call Transcript 06:30 pm July 31, 2026 at for the rest of the year, especially with the lens of Unloxcyt and Leqselvi, probably the launch costs are
Answer, jayashree satagopan
Jayashree Satagopan: So the other expenses have two, three components in it. One obviously is the launch cost that we had indicated early on last year for these two products, which is Leqselvi and Unloxcyt. But during the year, as we mentioned, the products in the initial years as they go through the commercialization, there would still be certain costs, and we need to continue to incur that. The second one, we should also be aware is that there is the forex element that is also contributing to the expenses last year to this year when we translate, I think that's something that we need to bear in mind. And in the current quarter, just as you would have heard us a little while ago, the R&D expenses have tracked a bit lower that will get normalized in the coming quarters. I think one need to look into all these three aspects as we analyze other expenditure.
Question
Kunal Dhamesha: Sure, ma'am. And...
Answer, richard ascroft
Richard Ascroft: Just to add a bit from the U.S. perspective since we're in the middle of launches. I think it's a bit of a misnomer to think there's a onetime expense on launch and then that expense goes away. It's a sustained investment to ensure you have a successful launch.
Question
Kunal Dhamesha: Okay. Okay. Perfect. And lastly, on the overall top line growth guidance, we had suggested for high single-digit growth versus this quarter, we have done almost 11% kind of a growth. So do you see an upside here from the full year perspective or we will stick to the high single-digit growth guidance as of now?
Answer, jayashree satagopan
Jayashree Satagopan: Think we should stick on to the high single-digit growth for the full year. Also, we should be a little mindful of the exchange-related impact that will come across all the line items in the P&L. Kunal Dhamesha: That should be overall positive, right? The translation effect would be positive on the revenue growth? Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY27 Earnings Call Transcript 06:30 pm July 31, 2026 Jayashree Satagopan: Yes.
Question
Kunal Dhamesha: So then is it conservative… Jayashree Satagopan: The current quarter, obviously it is positive, but we have to see how it translates for the rest of the year.
Answer, jayashree satagopan
Therefore, I would suggest that we should look at holding on to the overall guideline that we have shared with you earlier on.
Question
Neha Manpuria: Okay. Rick, on the U.S. generic business, there seem to be a very sharp step down in revenues, just roughly if I look at the numbers. I know you did mention some additional competition in certain products. Is that the only reason for the sharp decline in the U.S.? Is this the new base for the U.S. business -- U.S. generic business?
Answer, richard ascroft
Richard Ascroft: Yes. The largest part of the decline is Lenalidomide.
Answer, richard ascroft
Richard Ascroft: Slight decline based on the base business due to competition on a few products. But I mean, year-over-year, it's definitely Lenalidomide.
Answer, richard ascroft
As you know, we don't give product-wise specific targets. But as I said before, I think if you look at the inputs of number of prescribers, if you look at the market research and what we're hearing back from clinicians, all of this gives us very strong confidence in both of those two products.
Question
Neha Manpuria: No, sorry, I was talking about the U.S. generic business here, sorry?
Answer, richard ascroft
Richard Ascroft: I'm sorry. Yes, we did -- we just launched five new products, which, of course, will contribute to growth this past quarter towards the end of the quarter, and we have new launches this quarter as well.
Answer, abhishek sharma
Abhishek Sharma: But Neha, we are not guiding to the growth for specifically.
Question
Neha Manpuria: Understood. Understood. That's clear, Abhishek. And my second question is on the emerging market business. I think in the last 2 quarters, if I were to look at the USD growth, they were pretty strong, like high teens, 20%. This quarter seems to be 4%. Is t here any timing issue in supplies or anything that I need to be cognizant of in the quarter?
Answer, aalok shanghvi
Aalok Shanghvi: So, I think emerging markets, I would characterize the impact as a combination of both the geopolitical issues and difficult macroeconomic conditions in certain countries.
Answer, dilip shanghvi
But otherwise, I think we are creating a basket of products, which will help us continue to grow globally.
Question
Shashank Krishnakumar: Got it sir. And secondly, on Leqselvi. I think we have mentioned in the past that we could potentially look at other indications which other JAK inhibitors are also targeting. I think incrementally, we're also seeing data. I think one of our competitors has seen positive data in vitiligo as well. So when are we planning to sort of also try and target some of these other indications? And is the addressable market size also within these indications as meaningful as alopecia is, for instance? How are you looking at attacking some of those indications with Leqselvi?
Answer, dilip shanghvi
Dilip Shanghvi: I think Leqselvi is a very, what I would call good product in terms of its ability to significantly down regulate some of the important cytokines, which are involved in multiple autoimmune conditions. So we have to prioritize and identify areas where we can differentiate and register the product where when we come to the market, it's not very competitive. So if we -- whenever we initiate any study, I think we will keep that updated, and we will keep people updated about the progress of the disease. So both Leqselvi as well as Unloxcyt are potentially important opportunities for us to expand the current indi cations.
Answer, richard ascroft
Richard Ascroft: I might just add, we do -- we are conducting in the United States, investigator -initiated trials. And those, of course, can inform what Mr. Shanghvi just said.
Answer, dilip shanghvi
Dilip Shanghvi: So Rick, you are responding or... Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY27 Earnings Call Transcript 06:30 pm July 31, 2026 Richard Ascroft: Yes, I'm happy to respond.
Answer, richard ascroft
So both of these products are still pretty early in their growth curve, including an oncology product that just launched a few months ago. So I think give it time to be able to see the larger contribution. But we do continue to see good growth across the rest of our portfolio. I think for this quarter, as we mentioned, at least with one of our products, we do have seasonality, which is having a bit of an impact on the growth rates. But other than that, I think we have seen generally pretty strong growth out of the rest of the portfolio.
Question
Bino Pathiparampil: Understood. And just a repetition question on the generic part of the business. To one participant, I believe you mentioned that there is some cyclicality in the business, which led to a down quarter compared to the March quarter. At the same time, you also mentioned to somebody else that there were competitors, extra competition in some products. So do -- are both these reasons or is one more important reason?
Answer, abhishek sharma
Abhishek Sharma: Let me take that, Rick. I think, Bino, there are two different things we're talking about. The seasonality was on Q-o-Q basis for Levulan, not to do with generics. And the Y -o-Y comparison of was basically the additional competition factor that we gave.
Question
Bino Pathiparampil: Okay. Like the other expenses have come down Q-o-Q compared to March quarter. The depreciation and amortization costs have also come down compared to March quarter. Is there any particular reason? And what can we expect going forward?
Answer, jayashree satagopan
Jayashree Satagopan: There is no specific reason for this.
Question
If you can explain what's driving that? And also on semaglutide, various reasons being forwarded for some sort of slowdown after the initial spurt that we have seen. How are you seeing that market and opportunity? And the dynamics in India versus some of the other emerging markets that you are launching, how do you read that? Is that very different? And if you can give any comments based on the experience so far?
Answer, kirti ganorkar
Kirti Ganorkar: Sure. I think I will answer the first question. You're talking about the growth of India business. So I cannot pinpoint only to one thing which is driving the growth. It's like all the business units are doing good. And we are also focusing on generating a new prescription and brand building. So the entire part of the business and all the therapy areas are doing well.
Answer, kirti ganorkar
We also -- you also know we did a field force expansion in the past, and that is also helping us to grow the business in tier 2, tier 3 tiers. So all put together, I think all of these things are helping us to grow better than the market currently. Coming to your second question on semaglutide. And as we said in our readout also, we have become number 2 among the generic companies. And here also, our idea is to continuously grow above the market and gain market share. I don't know what you are referring to slowdown. I think there were some article about semaglutide generics inventory being increased in the market.
Answer, kirti ganorkar
But as far as Sun is concerned, I think we are doing well both on the prescription side and also on the value side and the unit growth also. So we see this is a very exciting and important opportunity. And also, we have a noveltreat, which is available in a format, which is auto -injector and which is also a very unique format in terms of use by the patients. And there are a lot of doctors and patients they are finding it quite user-friendly.
Question
Saion Mukherjee: Right, sir. And any comment on the emerging market opportunity, any dynamics there? Yes. The question was on the semaglutide because you got approval in Brazil, South Africa. So how are you seeing the opportunity in emerging markets?
Answer, aalok shanghvi
Aalok Shanghvi: I think to be honest, I think a little premature to be able to comment because I mean in this scenario, there are -- there's other companies -- other generic companies don't get approval. The opportunity is certainly much more attractive, but I highly doub t that to be the case. So our focus will be in ensuring and getting the product to the market and doing the best launch possible. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY27 Earnings Call Transcript 06:30 pm July 31, 2026 Saion Mukherjee: Okay.
Question
Just one other question on Unloxcyt and Leqselvi launches. It appears from your comment that initial traction is good. You're getting formulary access as per expectations. But in terms of revenue contribution, it might not be very significant. So for both these products, what's the time line for really seeing traction in revenues? What's the -- these are two different products. If you can guide us in terms of how long you think it takes for really the traction on revenues to come through?
Answer, richard ascroft
Richard Ascroft: Yes. We don't provide product -wise guidance that way. I would just say we expect to continue to see growth based on all of the indicators that we have today, whether that's increasing access, whether that's increasing the prescriber base, whether that's in creasing repeat prescriptions. So we do anticipate we'll continue to grow. But in terms of giving you a specific time line, we're not in a position to do that at this time.
Question
Saion Mukherjee: And is it like, Rick, one product like Leqselvi or Unloxcyt the dynamics different in terms of how quickly the traction can evolve or both of them is kind of more or less takes -- would take equal amount of time to get the traction?
Answer, kirti ganorkar
Kirti Ganorkar: Sure. I think as I already told in the readout and also here, we are growing higher than the market in terms of volume and new products. So if you dissect the growth into price growth, volume -led growth and new product growth. So 50% of our growth is comin g from volume and new products. So which is quite Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY27 Earnings Call Transcript 06:30 pm July 31, 2026 healthy, which also indicates that we are generating new prescription in the marketplace and which is way ahead of the IPM growth in terms of volume.
Question
Shyam Srinivasan: Got it. Helpful, sir. Just a second question on the comment about the tax rate, the ETR being higher. Ma'am, is it now like stand -alone Sun 28%, 29% is what we are assuming? Sorry, I missed the absolute percentage?
Answer, jayashree satagopan
Jayashree Satagopan: So we don't give stand-alone numbers. What I discussed about was primarily the consol number for Sun. And given that we have presence in various geographies and the tax rates in each of these geographies could be different. The overall ETR for this quarter was about 27.8%. And we expect this range to sort of continue for some time until we have the Organon transaction completed. Our endeavor, obviously, would be to look for areas to optimize the ETR, but we should look at this as a range.
Question
Surya Narayan Patra: My first question is on the global innovative business. Sir, if you can talk about the progress that you are witnessing on the global innovative business outside of the U.S. What is the current share in the overall mix currently? And what is likely to be g iven your aggressive activity that is visible by launching the specialty products outside of the U.S.?
Answer, abhishek sharma
Abhishek Sharma: Yes, we don't provide the breakup, Surya, for the innovative business by geography, yes. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY27 Earnings Call Transcript 06:30 pm July 31, 2026 Surya Narayan Patra: Okay.
Question
Kunal Dhamesha: One for Kirti on domestic market, would you internally be tracking prescription data for some of the key therapies?
Answer, kirti ganorkar
Kirti Ganorkar: We'll have prescription data. That's what we said in SMSRC, we are number 1 in 12 therapy areas. So we track both IQVIA, AWACS and the prescription data from various agencies, yes.
Question
Kunal Dhamesha: And based on that prescription data and the value growth you would have in some of the key therapies, are those kind of aligning very closely in recent months?
Answer, kirti ganorkar
Kirti Ganorkar: No, I can talk on Sun Pharma. That's what I would say, like I just alluded to the volume growth. So the way you should look at is if there's a volume growth, there is a prescription growth, which is coming. So our volume growth and the new prescription coming from new product, is 60% of our total growth. So 40% from volume, 20% from new products. So that clearly indicates that we are growing in a prescription. Corporate Office : Sun House, 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400063 For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com, Sun Pharma Q1 FY27 Earnings Call Transcript 06:30 pm July 31, 2026 Abhishek Sharma: And Kunal, we look at this variance, what you're suggesting.
Questions about this call
- When was the Sun Pharmaceutical Industries Q1 FY27 earnings call transcript filed?
- Sun Pharmaceutical Industries filed the transcript with the exchange on 6 Aug 2026. This page is built from that transcript.
- What does this page list?
- 28 statements from the transcript across 8 topics, 19 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 28 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.